Frontline Ceritinib Doubles PFS in ALK-Rearranged Lung Cancer

The oral ALK inhibitor ceritinib provided a significant improvement in progression-free survival over platinum-based chemotherapy in patients with previously untreated ALK-rearranged non-small-cell lung cancer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kyC3PS
via IFTTT